Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
30.03
+0.62 (2.11%)
Nov 9, 2026, 10:43 AM EST - Market open
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $55.39M in the quarter ending September 30, 2026, with 330.01% growth. This brings the company's total for the last twelve months to $140.84M, up 214.44% year-over-year. In the year 2025, Agios Pharmaceuticals had annual revenue of $54.03M with 48.03% growth. That makes Agios Pharmaceuticals the 20,099th largest company in the world by revenue and 3,082nd in the United States.
Revenue (ttm)
$140.84M
Revenue Growth
+214.44%
P/S Ratio
12.49
Revenue / Employee
$260,820
Employees
540
Market Cap
1.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.03M | 17.53M | 48.03% |
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nurix Therapeutics | 701.94M |
| Novavax | 411.65M |
| Mesoblast | 120.25M |
| Stoke Therapeutics | 28.21M |
| Generate Biomedicines | 26.48M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 11.00M |
| Lycia Therapeutics | 4.44M |
AGIO News
- 3 days ago - Agios Pharmaceuticals price target lowered to $48 from $50 at BofA - TheFly
- 3 days ago - Agios Pharmaceuticals price target raised to $62 from $55 at H.C. Wainwright - TheFly
- 3 days ago - Agios Pharmaceuticals price target lowered to $35 from $37 at Truist - TheFly
- 4 days ago - Agios Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 4 days ago - Agios Pharmaceuticals Earnings release: Q3 2026 - Filings
- 4 days ago - Agios Pharmaceuticals Slides: Q3 2026 - Filings
- 4 days ago - Agios Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 4 days ago - Agios Pharmaceuticals reports Q3 EPS ($1.09), consensus ($1.23) - TheFly